SBR 759

Drug Profile

SBR 759

Alternative Names: Phosphate binder - Novartis; SBR-759; Seboren

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SeBo GmbH
  • Developer Novartis
  • Class Disaccharides; Glucans; Iron compounds; Polymers
  • Mechanism of Action Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperphosphataemia

Most Recent Events

  • 01 Dec 2013 Discontinued - Phase-II for Hyperphosphataemia in Japan and Taiwan (PO)
  • 31 Aug 2012 No development reported - Phase-III for Hyperphosphataemia in Japan (PO)
  • 31 Dec 2007 Phase-II clinical trials in Hyperphosphataemia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top